Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025)

Dianthus Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $163.6 million for Q3 2025.

  • Quarterly results put Non-Current Assets at $163.6 million for Q3 2025, up 145.09% from a year ago — trailing twelve months through Sep 2025 was $396.8 million (up 439.68% YoY), and the annual figure for FY2024 was $93.1 million, up 4664.79%.
  • Non-Current Assets for Q3 2025 was $163.6 million at Dianthus Therapeutics, up from $62.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for DNTH hit a ceiling of $163.6 million in Q3 2025 and a floor of $1.0 million in Q3 2023.
  • Median Non-Current Assets over the past 4 years was $33.1 million (2022), compared with a mean of $44.0 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 96.85% in 2023 and later surged 6516.35% in 2024.
  • Dianthus Therapeutics' Non-Current Assets stood at $1.1 million in 2022, then soared by 81.43% to $2.0 million in 2023, then soared by 4664.79% to $93.1 million in 2024, then skyrocketed by 75.74% to $163.6 million in 2025.
  • The last three reported values for Non-Current Assets were $163.6 million (Q3 2025), $62.5 million (Q2 2025), and $77.6 million (Q1 2025) per Business Quant data.